A new study has revealed that a new class of drugs is showing promising results against migraine. According to study authors, in preliminary analysis Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies have been found effective in reducing the severe migraine headache.
Lead author Peter J. Goadsby, Chief of the UCSF Headache Center, and one of the world’s leading headache treatment experts and researchers, said that since the development of triptans back in 1991 there has not been any significant development towards prevention of migraine attacks. He further added that these medicines only just treat migraine attacks to give the patient some relief. However, there isn’t any drug that can reduce frequency of the severe migraine attacks.
While explaining Goadbsy said that the newly developed class of drugs significantly reduces levels of the peptide known as calcitonin gene-related peptide (CGRP), a key driver of migraine pain. He further added that companies including Alder Pharmaceuticals, Amgen, Eli Lilly and Company, and Teva Pharmaceuticals are already started testing several versions anti-CGRP therapies.
In clinical trials, it was found that the patients subject to the CGRP reported more than 50 percent reduction in the number of headache hours within a week they went under trials.
“The potential of these new compounds is enormous and gives us real hope that effective specific treatments for migraine may be on the near horizon,” Dr. Goadsby said. “The development of CGRP antibodies offers the simple, yet elegant and long awaited option for migraine patients to finally be treated with migraine preventives; it’s a truly landmark development.”
Although the drug has shown promising results but still it is under preliminary phase and more trials are needed to confirm its validity.